The health system will use the SOPHiA DDM™ Platform to help advance its research of blood cancers
BOSTON and Rolle, Switzerland, October 27, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the German company OnkoMedeor Diagnostics MVZ GmbH is now live on the SOPHiA DDM™ Platform. OnkoMedeor Diagnostics MVZ GmbH, which is a haematological lab and part of the Haematological Center Dachau (HAEZ) certified by the German Cancer Society (DKG), handles the diagnosis and treatment of blood and tumor diseases and will use SOPHiA GENETICS’ technology to expand its offerings, advance research and streamline workflow.
Chronic Lymphocytic Leukemia (CLL), which is classified as a lymphoid neoplasm, is among the most common type of blood cancer and affects more than 100,000 people globally. The SOPHiA DDM™ Platform is designed to compute a wide array of genomic variants and continually hone machine learning algorithms to detect rare and challenging cases. With the SOPHiA DDM™ Platform, OnkoMedeor Diagnostics MVZ GmbH will be able to increase detection of CLL, helping to improve patient care.
“The ability to produce trustworthy data that can classify CLL can make a tremendous difference in research and treatment planning,” said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. “The SOPHiA DDM™ Platform will help not only OnkoMedeor Diagnostics MVZ GmbH, but also its network of cancer treatment clinics, to enhance genetic testing and analysis capabilities via the AI and machine learning technology available with the SOPHiA DDM™ Platform. The enhanced capabilities will further its research and ultimately support the expanded use of precision medicine.”
The SOPHiA GENETICS solution used by OnkoMedeor Diagnostics MVZ GmbH is a customizable solution that enables precise characterization of lymphoid malignancy driver genes relevant for CLL. The solution uses next-generation sequencing and targets key variants from FFPE, blood, or bone marrow samples which can lead to better detection of the disease. Additionally, the SOPHiA DDM™ Platform offers tailored NGS-based workflows to streamline processes – from sample to report – to accelerate analysis.
By using the SOPHiA DDM™ Platform, researchers from OnkoMedeor Diagnostics MVZ GmbH will quickly obtain high-quality and reproducible data that will ultimately accelerate clinical research studies and advances the use of precision medicine.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on X (formerly known as Twitter), LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
SOPHiA DDM™ for Lymphoid Malignancies is available as a CE-IVD product for In Vitro Diagnostic Use in Europe and Turkey. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
[email protected]
References:
1https://www.sophiagenetics.com/clinical/oncology/blood-cancers/lymphoid-malignancies/#:~:text=SOPHiA%20DDM%E2%84%A2%EF%B8%8F%20Community%20CLL%20Clonality%20Solution%20is%20an%20expertly,mutational%20status%20and%20IGH%20rearrangements.
2https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753864/#:~:text=CLL%20accounts%20for%2025%E2%80%9330,in%20elderly%20populations%20%5B2%5D.
